EMA has recommended granting a marketing authorisation in the European Union (EU) for Imdylltra (tarlatamab) as monotherapy to treat adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease relapsed during or after an initial treatment with platinum-based chemotherapy.

SCLC is a rare, rapidly growing cancer associated with a poor prognosis. While many patients initially benefit from treatment with platinum-based chemotherapy, relapse is common. Treatment options following relapse are limited and outcomes remain poor, highlighting the need for new treatment options. Imdylltra provides a new targeted immunotherapy approach for these patients.

Imdylltra contains the active substance tarlatamab, a bispecific antibody that acts as a T-cell engager. It binds to the DLL3 protein on tumour cells and the CD3 protein on T cells, bringing them into close proximity. This activates T cells and leads to the production of inflammatory cytokines and the release of cytotoxic…